Adding durvalumab to perioperative FLOT improved EFS in patients with resectable gastric or GEJ cancer in the MATTERHORN ...

Adjuvant cemiplimab improved DFS in patients with CSCC who had completed adjuvant radiotherapy and had a high risk of recurrence.

Zanubrutinib plus venetoclax elicited durable responses in patients with treatment-naïve CLL or SLL and high-risk genetic features.

Adding nivolumab to adjuvant CRT improved DFS in patients with locally advanced head and neck squamous cell carcinoma at high risk of relapse.

Adding tagitanlimab to treatment with gemcitabine and cisplatin improved PFS in patients with recurrent or metastatic nasopharyngeal cancer.

The results of this phase III KEYNOTE-991 study do not support the addition of pembrolizumab to enzalutamide and ADT for the treatment of mHSPC,” researchers wrote.

As of this writing, the role of PD-L1 inhibitors in prostate cancer remains limited to a subset of patients with metastatic microsatellite instability-high, mismatch repair-deficient, or tumor ...

A reflex ctDNA-methylation MCED test can detect multiple cancer types in patients with obesity, a new study suggests.

A training platform integrated with AI can help pathologists identify HER2-low and HER2-ultralow breast cancers with more accuracy, data suggest.

Adding perioperative systemic therapy to CRS-HIPEC can improve some outcomes in patients with resectable colorectal peritoneal metastases, data suggest.

HHS Secretary Robert F. Kennedy Jr. said this week that he may no longer allow government scientists to publish research in top medical journals.

Escalating adjuvant treatment based on ctDNA positivity does not improve RFS in patients with stage III colon cancer, data suggest.